This study identifies TFCP2L1 as a novel molecular marker of bladder cancer that could help (i) elucidate further its pathogenesis, (ii) predict disease prognosis and treatment response to enable personalized medicine, and (iii) facilitate the development of novel therapeutics for the management of this aggressive disease. Here, TFCP2L1 is linked to urinary bladder carcinoma.